1. Home
  2. CRBP vs AEI Comparison

CRBP vs AEI Comparison

Compare CRBP & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$10.10

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Logo Alset Inc. (TX)

AEI

Alset Inc. (TX)

HOLD

Current Price

$1.77

Market Cap

119.4M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBP
AEI
Founded
2009
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building operators
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
119.4M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
CRBP
AEI
Price
$10.10
$1.77
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$45.60
N/A
AVG Volume (30 Days)
201.7K
16.1K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,822,272.00
$16,238,200.00
Revenue This Year
N/A
N/A
Revenue Next Year
$100.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
97.62
N/A
52 Week Low
$4.64
$0.70
52 Week High
$20.56
$4.55

Technical Indicators

Market Signals
Indicator
CRBP
AEI
Relative Strength Index (RSI) 62.24 43.23
Support Level $9.86 $1.47
Resistance Level $11.64 $2.11
Average True Range (ATR) 0.69 0.20
MACD 0.09 0.03
Stochastic Oscillator 83.54 29.42

Price Performance

Historical Comparison
CRBP
AEI

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About AEI Alset Inc. (TX)

Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.

Share on Social Networks: